How Investors Are Reacting To Amdocs (DOX) Slowing Sales Despite Rising Earnings And Low Valuation

• Amdocs has recently been highlighted for annual sales declines of 3.6% over the past two years and forecasts pointing to only 3.2% sales growth over the next 12 months, alongside a forward P/E of 6.8x that reflects cautious analyst sentiment about its near-term prospects.
• An interesting aspect is that, despite earnings per share increasing 8.1% annually and the telecom IT modernization theme remaining intact, analysts still appear hesitant about Amdocs’ growth trajectory compared with peers.
• We’ll now examine how weaker recent sales trends and a muted outlook may reshape Amdocs’ previously more optimistic investment narrative.

The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Amdocs Investment Narrative Recap

To own Amdocs, you need to believe that telecom IT modernization, data and AI driven services, and long term managed contracts can offset today’s soft demand signals. The recent news of a 3.6% sales decline over two years and only 3.2% forecast growth directly weighs on the near term growth catalyst and heightens the key risk that operators keep tightening transformation and capex budgets. If those spending constraints persist, the growth narrative could prove meaningfully weaker than before.

The most relevant recent announcement to this slowdown is Amdocs’ updated FY2026 guidance, which now calls for full year revenue growth of 2.6% to 4.6% and GAAP EPS growth of 12.0% to 15.0%. That guidance sits uncomfortably beside the softer sales backdrop, reinforcing that the core debate is whether earnings resilience and cost discipline can withstand sluggish top line momentum. For now, the guidance seems to acknowledge some pressure without pointing to a sharp break in the business model.

Yet behind the low 6.8x forward P E, there is an important risk investors should be aware of if large telecom clients keep delaying major projects and...

Read the full narrative on Amdocs (it's free!)

Amdocs' narrative projects $5.2 billion revenue and $832.7 million earnings by 2029. This requires 4.0% yearly revenue growth and about a $287 million earnings increase from $545.8 million today.

Uncover how Amdocs' forecasts yield a $81.21 fair value, a 57% upside to its current price.

Exploring Other Perspectives

Before this sales slowdown, the most optimistic analysts were assuming Amdocs could reach about US$5.2 billion of revenue and US$842.2 million of earnings by 2029, so their upbeat view of AI and cloud transformation, and the risk that higher AI spending might not scale as hoped, now contrasts sharply with today’s softer demand signals and invites you to consider how much those projections might shift.

Explore 7 other fair value estimates on Amdocs - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Amdocs research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free Amdocs research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amdocs' overall financial health at a glance.

Want Some Alternatives?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com